Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.42 (market cap $7.11B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.71 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 8.3× Norwegian Cruise Line Holdings Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| NCLH | TAK | |
|---|---|---|
Market Cap | $7.11B | $58.74B |
Volume | 22,683,268 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $19.05 |
52-Week Low | $14.12 | $13.23 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $21.93B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.495, up 2.96% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding expectations, and anticipates Q3 2026 results above guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Analyst consensus is a Buy with a $20.86 price target, indicating 34% upside potential. Recent news highlights strategic initiatives like earlier booking resets and new senior note offerings to manage debt.
The outlook for NCLH is positive, driven by earnings momentum and favorable analyst sentiment, but risks include persistent yield pressure and high debt levels. Investment opportunity lies in the stock's discounted valuation relative to growth prospects, though investors must monitor Caribbean pricing trends and the company's ability to sustain profitability amid macroeconomic uncertainties.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
